Abstract
Glucocorticoids (GCs) are widely used in medicine for treatment of chronic diseases. Especially in children, prolonged treatment causes growth retardation and early onset of osteoporosis. Human parathyroid hormone (PTH) has an anabolic effect on bone when administrated intermittently. The aim of the present study was to examine whether a combined therapy of dexamethasone (DEX) and PTH could prevent the detrimental effects of GC on cortical and trabecular bone in the femur and vertebrae of growing mice. Three-week-old female FVB mice were treated with control, DEX, PTH, or a combination of DEX and PTH by daily subcutaneous injections. After 4 weeks, animals were killed and the femur and L5 vertebra were isolated. Cortical and trabecular bone parameters and relative calcium density were measured by high-resolution X-ray micro-computed tomography (micro-CT). In the femur, PTH can reverse the effects of DEX on bone volume to control. However, it cannot reverse the undermineralization, which most likely is a strong contributor to bone fragility. In the vertebra, PTH improves bone volume to some extent but does not restore the values to normal. It augments the negative effect of DEX on mineralization. We conclude that the detrimental effects of DEX in the growing skeleton cannot be prevented by simultaneous PTH treatment.
Similar content being viewed by others
References
Chrysis D, Ritzen EM, Savendahl L (2003) Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 176:331–337
Silvestrini G, Ballanti P, Patacchioli FR, Mocetti P, Di GR, Wedard BM, Angelucci L, Bonucci E (2000) Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone 26:33–42
van der Eerden BC, Karperien M, Wit JM (2003) Systemic and local regulation of the growth plate. Endocr Rev 24:782–801
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633
Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282
O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328
Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC (2002) Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041–1048
Canalis E, Delany AM (2002) Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 966:73–81
Van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129–137
Balooch G, Yao W, Ager JW, Balooch M, Nalla RK, Porter AE, Ritchie RO, Lane NE (2007) The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of clucocorticoids. Arthritis Rheum 56:3726–3737
Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M (2001) Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16:1665–1673
Gittens SA, Wohl GR, Zernicke RF, Matyas JR, Morley P, Uludag H (2004) Systemic bone formation with weekly PTH administration in ovariectomized rats. J Pharm Pharm Sci 7:27–37
Yao W, Cheng Z, Pham A, Busse C, Zimmerman EA, Ritchie RO, Lane NE (2008) Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485–3497
Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039
van Buul-Offers SC, Smink JJ, Gresnigt R, Hamers N, Koedam J, Karperien M (2005) Thyroid hormone, but not parathyroid hormone, partially restores glucocorticoid-induced growth retardation. Pediatr Nephrol 20:335–341
Waarsing JH, Day JS, van der Linden JC, Ederveen AG, Spanjers C, De Clerck N, Sasov A, Verhaar JA, Weinans H (2004) Detecting and tracking local changes in the tibiae of individual rats: a novel method to analyse longitudinal in vivo micro-CT data. Bone 34:163–169
De Clerck N, Postnov A (2007) High resolution X-ray microtomography: applications in biomedical research. In: Tavitian B, Leroy-Willig A, Ntziachristos V (eds) International textbook of in vivo imaging in vertebrates. Wiley, London, pp 57–77
Rooman R, Koster G, Bloemen R, Gresnigt R, van Buul-Offers SC (1999) The effect of dexamethasone on body and organ growth of normal and IGF-II transgenic mice. J Endocrinol 163:543–552
Smink JJ, Gresnigt MG, Hamers N, Koedam JA, Berger R, Van Buul-Offers SC (2003) Short-term glucocorticoid treatment of prepubertal mice decreases growth and IGF-I expression in the growth plate. J Endocrinol 177:381–388
Mohan S, Kutilek S, Zhang C, Shen HG, Kodama Y, Srivastava AK, Wergedal JE, Beamer WG, Baylink DJ (2000) Comparison of bone formation responses to parathyroid hormone (1–34), (1–31), and (2–34) in mice. Bone 27:471–478
Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S (2001) Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349–4356
Feldkamp LA, Davis LC, Kress JW (1984) Practical cone-beam algorithm. J Opt Soc Am A1:612–619
Postnov A, Vinogradov A, Van Dyck D, Saveliev SV, De Clerck NM (2003) Quantitative analysis of bone mineral content by X-ray microtomography. Physiol Meas 24:165–178
Iwamoto J, Matsumoto H, Takeda T, Sato Y, Liu X, Yeh JK (2008) Effects of vitamin K2 and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int 83:121–128
McLaughlin F, Mackintosh J, Hayes BP, McLaren A, Uings IJ, Salmon P, Humphreys J, Meldrum E, Farrow SN (2002) Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone 30:924–930
Ikeda S, Morishita Y, Tsutsumi H, Ito M, Shiraishi A, Arita S, Akahoshi S, Narusawa K, Nakamura T (2003) Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 33:779–787
Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434–1446
Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262–272
Oxlund H, Ortoft G, Thomsen JS, Danielsen CC, Ejersted C, Andreassen TT (2006) The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39:244–252
Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J, Insogna K (2005) The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146:1983–1990
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Postnov, A., De Schutter, T., Sijbers, J. et al. Glucocorticoid-Induced Osteoporosis in Growing Mice Is Not Prevented by Simultaneous Intermittent PTH Treatment. Calcif Tissue Int 85, 530–537 (2009). https://doi.org/10.1007/s00223-009-9301-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-009-9301-3